Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants. The Spravato device delivers the first monotherapy for adults with treatment-resistant depression. Administration through the nasal spray device allows for rapid absorption of the active ingredient, esketamine, directly into the bloodstream through the nasal mucosa.
Spravato Device and Packaging
Proper usage of the device to realize the full benefit of the drug required unlearning certain ingrained behaviors. This proved to be challenging because nasal spray devices are common in the consumer OTC space, but this device requres a specific insertion angle and depth into the nasal cavity to target the nasal mucosa. Through countless iterations, prototypes, and human factors studies, the nasal guide plate and finger flange that was developed facilitates proper usage, ensuring patients are getting the therapy they need. The FDA granted esketamine Breakthrough Therapy Designation in 2013 for treatment-resistant depression (TRD) and in 2016 for major depressive disorder (MDD) with suicidal intent.
